Vertex Pharmaceuticals Trading Volume Ranks 89th as Stock Rises for Fifth Consecutive Day

On April 28, 2025, Vertex Pharmaceuticals (VRTX) saw a trading volume of $744 million, ranking 89th in the day's market activity. The stock rose by 0.54%, marking its fifth consecutive day of gains and a 3.97% increase over the past five days.

Vertex Pharmaceuticals received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for ALYFTREK®, a new once-daily CFTR modulator for the treatment of cystic fibrosis. If approved, this medication would be indicated for patients aged 6 and older with at least one non-class I mutation, expanding the potential patient base significantly.

This positive opinion from the CHMP is a significant milestone for Vertex, as it paves the way for potential approval and commercialization of ALYFTREK®. The approval and subsequent commercialization of ALYFTREK®, along with JOURNAVX, are expected to drive revenue growth by setting new treatment standards and diversifying Vertex's market presence.